|
|
|
| 异质性 | ||
| N | WMD (95% CI) | 组内P值 | P值 | I2% | 亚组间P值 |
HbA1C亚组 |
|
|
|
|
|
|
总效应量 | 11 | −0.506 (−0.786, −0.227) | <0.001 | <0.001 | 74.2 |
|
HbA1C基线水平 |
|
|
|
|
|
|
≤9% | 2 | −0.752 (−1.426, −0.077) | 0.029 | 0.003 | 88.8 | <0.001 |
>9% | 9 | −0.414 (−0.772, −0.057) | 0.023 | <0.001 | 72.9 |
|
疗程(月) |
|
|
|
|
|
|
≤3 | 8 | −0.658 (−0.955, −0.361) | <0.001 | <0.001 | 74.3 | <0.001 |
>3 | 3 | 0.128 (−0.728, 0.983) | 0.770 | 0.021 | 74.1 |
|
使用其他降糖药 |
|
|
|
|
|
|
否 | 2 | −0.951 (−2.027, 0.126) | 0.083 | <0.001 | 93.0 | <0.001 |
是 | 9 | −0.397 (−0.710, −0.083) | 0.013 | 0.002 | 67.0 |
|
Scr亚组 |
|
|
|
|
|
|
总效应量 | 7 | −8.210 (−12.548, −3.872) | <0.001 | <0.001 | 88.2 |
|
Scr基线水平 |
|
|
|
|
| |
>100 μmol/L | 1 | −27.430 (−35.100, −19.760) | <0.001 | - | - | <0.001 |
≤100 μmol/L | 6 | −5.704 (−9.385, −2.022) | 0.002 | <0.001 | 82.9 |
|
疗程(月) |
|
|
|
|
|
|
≤3 | 4 | −11.021 (−15.182, −6.861) | <0.001 | <0.001 | 88.7 | <0.001 |
>3 | 3 | 0.701 (−3.351, 4.752) | 0.735 | 0.772 | 0 |
|
使用其他降糖药 |
|
|
|
|
|
|
否 | 2 | −18.118 (−35.512, −0.724) | 0.041 | <0.001 | 95.1 | <0.001 |
是 | 5 | −4.220 (−8.432, −0.007) | 0.05 | 0.018 | 66.3 |
|
BUN亚组 |
|
|
|
|
|
|
总效应量 | 6 | −1.224 (−1.674, −0.774) | <0.001 | <0.001 | 92.6 |
|
BNU基线水平 |
|
|
|
|
| |
≥7.5 mmol/L | 1 | −2.140 (−2.552, −1.728) | <0.001 | - | - | <0.001 |
<7.5 mmol/L | 5 | −1.051 (−1.527, −0.576) | <0.001 | <0.001 | 92.6 |
|
疗程(月) |
|
|
|
|
|
|
≤3 | 5 | −1.456 (−1.756, −1.155) | <0.001 | <0.001 | 81.3 | <0.001 |
>3 | 1 | 0.040 (−0.389, 0.469) | 0.855 | - | - |
|
使用其他降糖药 |
|
|
|
|
|
|
否 | 2 | −1.821 (−2.375, −1.266) | <0.001 | 0.10 | 84.9 | <0.001 |
是 | 4 | −0.907 (−1.448, −0.365) | 0.001 | <0.001 | 89.0 |
|
使用RAASi |
|
|
|
|
|
|
否 | 5 | −1.225 (−1.758, −0.693) | <0.001 | <0.001 | 94 | <0.001 |
是 | 1 | −1.210 (−1.592, −0.828) | <0.001 | - | - |
|
UACR亚组 |
|
|
|
|
|
|
总效应量 | 5 | −20.940 (−32.888, −8.992) | <0.001 | <0.001 | 86.8 |
|
疗程(月) |
|
|
|
|
|
|
≤3 | 4 | −15.832 (−26.057, −5.608) | 0.0012 | 0.005 | 76.7 | <0.001 |
>3 | 1 | −40.490 (−51.285, −29.695) | <0.001 | - | - |
|
使用其他降糖药 |
|
|
|
|
|
|
否 | 1 | −9.360 (−14.951, −3.769) | 0.001 | - | - | 0.001 |
是 | 4 | −25.204 (−36.776, −13.632) | <0.001 | 0.018 | 70.3 |
|
使用RAASi |
|
|
|
|
|
|
否 | 4 | −19.697 (−37.474, −1.920) | 0.030 | <0.001 | 88.1 | <0.001 |
是 | 1 | −24.370 (−30.418, −18.322) | <0.001 | - | - |
|
eGFR亚组 |
|
|
|
|
|
|
总效应量 | 4 | −3.310 (−13.073, 6.454) | 0.506 | <0.001 | 87.4 |
|
eGFR基线水平(ml/min/1.73 m2) |
|
|
|
| ||
<90 | 1 | 2.640 (−2.014, 7.294) | 0.266 | - | - | <0.001 |
≥90 | 3 | −7.405 (−15.277, 0.468) | 0.065 | 0.166 | 44.3 |
|
疗程(月) |
|
|
|
|
|
|
≤3 | 3 | −7.405 (−15.277, 0.468) | 0.065 | 0.166 | 44.3 | <0.001 |
>3 | 1 | 2.640 (−2.014, 7.294) | 0.266 | - | - |
|
使用RAASi |
|
|
|
|
|
|
否 | 5 | 1.987 (−2.254, 6.229) | 0.358 | 0.777 | 0 | <0.001 |
是 | 1 | −11.670 (−15.224, −8.116) | <0.001 | - | - |
|